{"filing":{"accession_number":"0001567264-26-000061","cik":"0001567264","ticker":"INTS","company_name":"INTENSITY THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"intensity-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1567264/000156726426000061/intensity-20260811.htm"},"events":[{"id":26882,"run_id":24450,"accession_number":"0001567264-26-000061","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Intensity Therapeutics' financial results for the three and six months ended June 30, 2026. The filing explicitly states \"On August 11, 2026, Intensity Therapeutics, Inc. released its financial results for the three and six months ended June 30, 2026\" with a press release attached as Exhibit 99.1. The press release includes quarterly financial data (R\u0026D expenses, G\u0026A expenses, net loss, cash position) and is material to investors assessing the company's financial condition and operational progress.","company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28171,"accession_number":"0001567264-26-000061","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Intensity Therapeutics' financial results for the three and six months ended June 30, 2026. The filing explicitly states \"On August 11, 2026, Intensity Therapeutics, Inc. released its financial results for the three and six months ended June 30, 2026\" with a press release attached as Exhibit 99.1. The press release includes quarterly financial data (R\u0026D expenses, G\u0026A expenses, net loss, cash position) and is material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:41:37.262098+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28171,"accession_number":"0001567264-26-000061","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Intensity Therapeutics' financial results for the three and six months ended June 30, 2026. The filing explicitly states \"On August 11, 2026, Intensity Therapeutics, Inc. released its financial results for the three and six months ended June 30, 2026\" with a press release attached as Exhibit 99.1. The press release includes quarterly financial data (R\u0026D expenses, G\u0026A expenses, net loss, cash position) and is material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:41:37.262098+00:00","company_name":"INTENSITY THERAPEUTICS, INC.","ticker":"INTS","filing_date":"2026-08-11"}]}